Prolidase, a potential enzyme target for melanoma: Design of proline-containing dipeptide-like prodrugs

Sachin Mittal, Xueqin Song, Balvinder S. Vig, Christopher P. Landowski, Insook Kim, John M. Hilfinger, Gordon L. Amidon

Research output: Contribution to journalArticleScientificpeer-review

32 Citations (Scopus)

Abstract

Bioinformatics tools such as Perl, Visual Basic, Cluster, and TreeView were used to analyze public gene expression databases in order to identify potential enzyme targets for prodrug strategies. The analyses indicated that prolidase might be a desirable enzyme target based on its differential expression in melanoma cancer cell lines and its high substrate specificity for dipeptides containing proline at the carboxy terminus. RT-PCR expression of prolidase and hydrolytic activity against N-glycyl-L-proline (GLY-PRO), a standard substrate of prolidase, determined in tumor cell lines, exhibited a high correlation (r 2 = 0.95). These results suggest the possibility of targeting prolidase with prodrugs of anticancer agents for enhanced selectivity. The feasibility of such a scenario was tested by (a) synthesizing prodrugs of melphalan that comprised linkage of the carboxy terminus of the L-phenylalanine moiety of melphalan to the N-terminus of L and D stereoisomers of proline and (b) determining their bioconversion and antiproliferative activities in SK-MEL-5 cells, a melanoma cancer cell line with high expression levels of prolidase. The results of hydrolysis studies of the L- and D-proline prodrugs of melphalan, designated as prophalan-L and prophalan-D, respectively, indicated a ∼7-fold higher rate of activation of prophalan-L compared to prophalan-D in SK-MEL-5 cell homogenates. Prophalan-L exhibited cytotoxicity (Gl 50 = 74.8 μM) comparable to that of melphalan (Gl 50 = 57.0 μM) in SK-MEL-5 cells while prophalan-D was ineffective, suggesting that prolidase-specific activation to the parent drug may be essential for cytotoxic action. Thus, melphalan prodrugs such as prophalan-L that are cleavable by prolidase offer the potential for enhanced selectivity by facilitating cytotoxic activity only in cells overexpressing prolidase.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalMolecular Pharmaceutics
Volume2
Issue number1
DOIs
Publication statusPublished - 1 Jan 2005
MoE publication typeA1 Journal article-refereed

Fingerprint

proline dipeptidase
Dipeptides
Prodrugs
Proline
Melanoma
Melphalan
Enzymes
glycylproline
Cell Line
Stereoisomerism
Substrate Specificity
prophalan
Computational Biology
Tumor Cell Line
Phenylalanine
Antineoplastic Agents
Neoplasms
Hydrolysis

Keywords

  • Bioinformatics
  • Enzyme targeting
  • Melanoma
  • Melphalan
  • Prodrugs
  • Prolidase

Cite this

Mittal, Sachin ; Song, Xueqin ; Vig, Balvinder S. ; Landowski, Christopher P. ; Kim, Insook ; Hilfinger, John M. ; Amidon, Gordon L. / Prolidase, a potential enzyme target for melanoma : Design of proline-containing dipeptide-like prodrugs. In: Molecular Pharmaceutics. 2005 ; Vol. 2, No. 1. pp. 37-46.
@article{9651544d587249f2857ccd209bcb345d,
title = "Prolidase, a potential enzyme target for melanoma: Design of proline-containing dipeptide-like prodrugs",
abstract = "Bioinformatics tools such as Perl, Visual Basic, Cluster, and TreeView were used to analyze public gene expression databases in order to identify potential enzyme targets for prodrug strategies. The analyses indicated that prolidase might be a desirable enzyme target based on its differential expression in melanoma cancer cell lines and its high substrate specificity for dipeptides containing proline at the carboxy terminus. RT-PCR expression of prolidase and hydrolytic activity against N-glycyl-L-proline (GLY-PRO), a standard substrate of prolidase, determined in tumor cell lines, exhibited a high correlation (r 2 = 0.95). These results suggest the possibility of targeting prolidase with prodrugs of anticancer agents for enhanced selectivity. The feasibility of such a scenario was tested by (a) synthesizing prodrugs of melphalan that comprised linkage of the carboxy terminus of the L-phenylalanine moiety of melphalan to the N-terminus of L and D stereoisomers of proline and (b) determining their bioconversion and antiproliferative activities in SK-MEL-5 cells, a melanoma cancer cell line with high expression levels of prolidase. The results of hydrolysis studies of the L- and D-proline prodrugs of melphalan, designated as prophalan-L and prophalan-D, respectively, indicated a ∼7-fold higher rate of activation of prophalan-L compared to prophalan-D in SK-MEL-5 cell homogenates. Prophalan-L exhibited cytotoxicity (Gl 50 = 74.8 μM) comparable to that of melphalan (Gl 50 = 57.0 μM) in SK-MEL-5 cells while prophalan-D was ineffective, suggesting that prolidase-specific activation to the parent drug may be essential for cytotoxic action. Thus, melphalan prodrugs such as prophalan-L that are cleavable by prolidase offer the potential for enhanced selectivity by facilitating cytotoxic activity only in cells overexpressing prolidase.",
keywords = "Bioinformatics, Enzyme targeting, Melanoma, Melphalan, Prodrugs, Prolidase",
author = "Sachin Mittal and Xueqin Song and Vig, {Balvinder S.} and Landowski, {Christopher P.} and Insook Kim and Hilfinger, {John M.} and Amidon, {Gordon L.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1021/mp049922p",
language = "English",
volume = "2",
pages = "37--46",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society ACS",
number = "1",

}

Prolidase, a potential enzyme target for melanoma : Design of proline-containing dipeptide-like prodrugs. / Mittal, Sachin; Song, Xueqin; Vig, Balvinder S.; Landowski, Christopher P.; Kim, Insook; Hilfinger, John M.; Amidon, Gordon L.

In: Molecular Pharmaceutics, Vol. 2, No. 1, 01.01.2005, p. 37-46.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Prolidase, a potential enzyme target for melanoma

T2 - Design of proline-containing dipeptide-like prodrugs

AU - Mittal, Sachin

AU - Song, Xueqin

AU - Vig, Balvinder S.

AU - Landowski, Christopher P.

AU - Kim, Insook

AU - Hilfinger, John M.

AU - Amidon, Gordon L.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Bioinformatics tools such as Perl, Visual Basic, Cluster, and TreeView were used to analyze public gene expression databases in order to identify potential enzyme targets for prodrug strategies. The analyses indicated that prolidase might be a desirable enzyme target based on its differential expression in melanoma cancer cell lines and its high substrate specificity for dipeptides containing proline at the carboxy terminus. RT-PCR expression of prolidase and hydrolytic activity against N-glycyl-L-proline (GLY-PRO), a standard substrate of prolidase, determined in tumor cell lines, exhibited a high correlation (r 2 = 0.95). These results suggest the possibility of targeting prolidase with prodrugs of anticancer agents for enhanced selectivity. The feasibility of such a scenario was tested by (a) synthesizing prodrugs of melphalan that comprised linkage of the carboxy terminus of the L-phenylalanine moiety of melphalan to the N-terminus of L and D stereoisomers of proline and (b) determining their bioconversion and antiproliferative activities in SK-MEL-5 cells, a melanoma cancer cell line with high expression levels of prolidase. The results of hydrolysis studies of the L- and D-proline prodrugs of melphalan, designated as prophalan-L and prophalan-D, respectively, indicated a ∼7-fold higher rate of activation of prophalan-L compared to prophalan-D in SK-MEL-5 cell homogenates. Prophalan-L exhibited cytotoxicity (Gl 50 = 74.8 μM) comparable to that of melphalan (Gl 50 = 57.0 μM) in SK-MEL-5 cells while prophalan-D was ineffective, suggesting that prolidase-specific activation to the parent drug may be essential for cytotoxic action. Thus, melphalan prodrugs such as prophalan-L that are cleavable by prolidase offer the potential for enhanced selectivity by facilitating cytotoxic activity only in cells overexpressing prolidase.

AB - Bioinformatics tools such as Perl, Visual Basic, Cluster, and TreeView were used to analyze public gene expression databases in order to identify potential enzyme targets for prodrug strategies. The analyses indicated that prolidase might be a desirable enzyme target based on its differential expression in melanoma cancer cell lines and its high substrate specificity for dipeptides containing proline at the carboxy terminus. RT-PCR expression of prolidase and hydrolytic activity against N-glycyl-L-proline (GLY-PRO), a standard substrate of prolidase, determined in tumor cell lines, exhibited a high correlation (r 2 = 0.95). These results suggest the possibility of targeting prolidase with prodrugs of anticancer agents for enhanced selectivity. The feasibility of such a scenario was tested by (a) synthesizing prodrugs of melphalan that comprised linkage of the carboxy terminus of the L-phenylalanine moiety of melphalan to the N-terminus of L and D stereoisomers of proline and (b) determining their bioconversion and antiproliferative activities in SK-MEL-5 cells, a melanoma cancer cell line with high expression levels of prolidase. The results of hydrolysis studies of the L- and D-proline prodrugs of melphalan, designated as prophalan-L and prophalan-D, respectively, indicated a ∼7-fold higher rate of activation of prophalan-L compared to prophalan-D in SK-MEL-5 cell homogenates. Prophalan-L exhibited cytotoxicity (Gl 50 = 74.8 μM) comparable to that of melphalan (Gl 50 = 57.0 μM) in SK-MEL-5 cells while prophalan-D was ineffective, suggesting that prolidase-specific activation to the parent drug may be essential for cytotoxic action. Thus, melphalan prodrugs such as prophalan-L that are cleavable by prolidase offer the potential for enhanced selectivity by facilitating cytotoxic activity only in cells overexpressing prolidase.

KW - Bioinformatics

KW - Enzyme targeting

KW - Melanoma

KW - Melphalan

KW - Prodrugs

KW - Prolidase

UR - http://www.scopus.com/inward/record.url?scp=14644445992&partnerID=8YFLogxK

U2 - 10.1021/mp049922p

DO - 10.1021/mp049922p

M3 - Article

C2 - 15804176

AN - SCOPUS:14644445992

VL - 2

SP - 37

EP - 46

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 1

ER -